Sector News

Glaxo's Waterhouse tapped to replace ViiV Healthcare CEO

December 6, 2016
Life sciences

The exec exodus at GlaxoSmithKline is continuing—and so is the rise of women to the company’s top ranks.

Monday, the British pharma giant announced that Dominique Limet, head of HIV unit ViiV Healthcare, would step down at the end of March 2017—the same month the company will bid farewell to longtime CEO Andrew Witty. He’ll be replaced by Deborah Waterhouse, who currently serves as GSK’s SVP of primary care, and VP of U.S. primary care sales Cheryl MacDiarmid will step in for Waterouse.

The moves are part of a larger game of “musical execs” for Glaxo, which began with the Witty announcement in March. In September, the company announced that then consumer chief Emma Walmsley would take the company lead as Big Pharma’s first woman CEO, and it shortly thereafter named ex-Novartis consumer vet Brian McNamara as Walmsley’s successor. Meanwhile, vaccines chief Moncef Slaoui, a longtime Glaxo leader, is also set to hit the exit, with his departure slated for June 30.

It wasn’t all that long ago that ViiV’s fate was up in the air. In late 2014, the company floated the idea of a unit spinoff among its investors, but their responses—as well as standout performances from new meds Tivicay and Triumeq, at a time when the company’s respiratory contenders weren’t getting it done—convinced GSK to drop the idea.

Shareholders gave “very strong feedback that we should retain that business,” Witty said last October, pointing out that, over the course of the deliberation period, expectations for the business grew “almost exponentially.”

“We took the decision not to separate it because we believed we were the best owners,” he said. “And I think we’ve been vindicated since.”

Meanwhile, the job of keeping that momentum going will now fall to Waterhouse, who has worked in marketing, sales, and even R&D in her 20-year Glaxo career. While a rebounding respiratory lineup has helped take some of the companywide pressure off of ViiV, the division is still locked in a market share battle with HIV rival Gilead, and its plans to surge ahead depend on a high-stakes bet on two-drug regimens.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach